Pulmonary FibrosisPhase 3NCT01335464
Safety and Efficacy of BIBF 1120 at High Dose in Idiopathic Pulmonary Fibrosis Patients
A Phase 3 study testing BIBF 1120 in people with Pulmonary Fibrosis, run by Boehringer Ingelheim at 98 sites in 13 countries.
Trial summary
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the death rate. Read more about this study
- Who is it for?
- Ages 40 years and older
- Conditions the study is for
- Pulmonary Fibrosis
- What is being tested?
- BIBF 1120
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 515 participants
- Where
- 98 sitesin 13 countries
- Study dates
- Apr 2011to Oct 2013
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age >= 40 years;
- IPF diagnosed, according to most recent American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management, within 5 years;
- Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of IPF
- Dlco (corrected for Hb): 30%-79% predicted of normal;
- FVC>= 50% predicted of normal
Who cannot join
- Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit of Normal (ULN)
- Bilirubin > 1.5 x ULN;
- Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);
- Patient likely to have lung transplantation during study (being on transplantation list is acceptable for participation);
- Myocardial infarction within 6 months;
- Unstable angina within 1 month;
Show all 11Show fewer
- Bleeding risk (genetic predisposition; fibrinolysis or full-dose therapeutic anticoagulation or high dose antiplatelet therapy; history of hemorrhagic CNS event within 12 months; haemoptysis or haematuria or active gastro-intestinal bleeding or ulcers or major injury or surgery within 3 months);
- Thrombotic risk (inherited predisposition; history of thrombotic event (including stroke and transient ischemic attacks) within 12 months;
- International normalised ratio (INR) > 2, prolongation of prothrombin time (PT) and partial thromboplastin time (PTT) by > 50% of institutional ULN);
- N-ACetyl Cystein, prednisone > 15mg/day or equivalent received within 2 weeks of visit 1;
- Pirfenidone, azathioprine, cyclophosphamide, cyclosporine A received within 8 weeks of visit 1;
Trial locations and contacts
98 sites in 13 countries.
98 sites in 13 countries
United States24 sites
1199.32.10007 Boehringer Ingelheim Investigational Site
Birmingham, Alabama
1199.32.10004 Boehringer Ingelheim Investigational Site
Cincinnati, Ohio
1199.32.10001 Boehringer Ingelheim Investigational Site
Council Bluffs, Iowa
1199.32.10009 Boehringer Ingelheim Investigational Site
Dallas, Texas
1199.32.10022 Boehringer Ingelheim Investigational Site
Danbury, Connecticut
1199.32.10021 Boehringer Ingelheim Investigational Site
Falls Church, Virginia
1199.32.10029 Boehringer Ingelheim Investigational Site
Jasper, Alabama
1199.32.10005 Boehringer Ingelheim Investigational Site
Los Angeles, California
1199.32.10003 Boehringer Ingelheim Investigational Site
Lynchburg, Virginia
1199.32.10018 Boehringer Ingelheim Investigational Site
McKinney, Texas
1199.32.10016 Boehringer Ingelheim Investigational Site
Minneapolis, Minnesota
1199.32.10015 Boehringer Ingelheim Investigational Site
Nashville, Tennessee
1199.32.10024 Boehringer Ingelheim Investigational Site
New Brunswich, New Jersey
1199.32.10019 Boehringer Ingelheim Investigational Site
New York, New York
1199.32.10025 Boehringer Ingelheim Investigational Site
Newark, Delaware
1199.32.10013 Boehringer Ingelheim Investigational Site
Phoenix, Arizona
1199.32.10002 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania
1199.32.10033 Boehringer Ingelheim Investigational Site
Pittsburgh, Pennsylvania
1199.32.10020 Boehringer Ingelheim Investigational Site
Portland, Oregon
1199.32.10008 Boehringer Ingelheim Investigational Site
Providence, Rhode Island
1199.32.10034 Boehringer Ingelheim Investigational Site
Shelbyville, Tennessee
1199.32.10038 Boehringer Ingelheim Investigational Site
Tacoma, Washington
1199.32.10023 Boehringer Ingelheim Investigational Site
Weston, Florida
1199.32.10028 Boehringer Ingelheim Investigational Site
Wichita, Kansas
Italy12 sites
1199.32.39012 Boehringer Ingelheim Investigational Site
Catania
1199.32.39004 Boehringer Ingelheim Investigational Site
Chieti Scalo
1199.32.39008 Boehringer Ingelheim Investigational Site
Forlì
1199.32.39005 Boehringer Ingelheim Investigational Site
Milan
1199.32.39001 Boehringer Ingelheim Investigational Site
Modena
1199.32.39007 Boehringer Ingelheim Investigational Site
Monza
1199.32.39011 Boehringer Ingelheim Investigational Site
Naples
1199.32.39002 Boehringer Ingelheim Investigational Site
Padova
1199.32.39006A Boehringer Ingelheim Investigational Site
Pisa
1199.32.39006B Boehringer Ingelheim Investigational Site
Pisa
1199.32.39010 Boehringer Ingelheim Investigational Site
Roma
1199.32.39009 Boehringer Ingelheim Investigational Site
Siena
Japan12 sites
1199.32.81005 Boehringer Ingelheim Investigational Site
Bunkyo-ku,Tokyo
1199.32.81006 Boehringer Ingelheim Investigational Site
Bunkyo-ku,Tokyo
1199.32.81007 Boehringer Ingelheim Investigational Site
Kiyose, Tokyo
1199.32.81004 Boehringer Ingelheim Investigational Site
Kumagaya, Saitama
1199.32.81009 Boehringer Ingelheim Investigational Site
Minato-ku, Tokyo
1199.32.81003 Boehringer Ingelheim Investigational Site
Naka-gun, Ibaraki
1199.32.81011 Boehringer Ingelheim Investigational Site
Ota-ku, Tokyo
1199.32.81001 Boehringer Ingelheim Investigational Site
Sendai, Miyagi
1199.32.81010 Boehringer Ingelheim Investigational Site
Shibuya-ku, Tokyo
1199.32.81002 Boehringer Ingelheim Investigational Site
Shimotsuke,Tochigi
1199.32.81008 Boehringer Ingelheim Investigational Site
Shinjuku-ku, Tokyo
1199.32.81012 Boehringer Ingelheim Investigational Site
Yokohama, Kanagawa
Germany8 sites
1199.32.49008 Boehringer Ingelheim Investigational Site
Bamberg
1199.32.49005 Boehringer Ingelheim Investigational Site
Donaustauf
1199.32.49001 Boehringer Ingelheim Investigational Site
Essen
1199.32.49002 Boehringer Ingelheim Investigational Site
Freiburg/Breisgau
1199.32.49006 Boehringer Ingelheim Investigational Site
Giessen
1199.32.49003 Boehringer Ingelheim Investigational Site
Großhansdorf
1199.32.49007 Boehringer Ingelheim Investigational Site
Heidelberg
1199.32.49004 Boehringer Ingelheim Investigational Site
Mainz
United Kingdom8 sites
1199.32.44006 Boehringer Ingelheim Investigational Site
Aberdeen
1199.32.44003 Boehringer Ingelheim Investigational Site
Birmingham
1199.32.44005 Boehringer Ingelheim Investigational Site
Birmingham
1199.32.44009 Boehringer Ingelheim Investigational Site
Leeds
1199.32.44004 Boehringer Ingelheim Investigational Site
Liverpool
1199.32.44002 Boehringer Ingelheim Investigational Site
London
1199.32.44008 Boehringer Ingelheim Investigational Site
Oxford
1199.32.44001 Boehringer Ingelheim Investigational Site
Westbury on Trym
France7 sites
1199.32.33002 Boehringer Ingelheim Investigational Site
Bobigny
1199.32.33003 Boehringer Ingelheim Investigational Site
Nice
1199.32.33001 Boehringer Ingelheim Investigational Site
Paris
1199.32.33005 Boehringer Ingelheim Investigational Site
Paris
1199.32.33006 Boehringer Ingelheim Investigational Site
Paris
1199.32.33007 Boehringer Ingelheim Investigational Site
Reims
1199.32.33004 Boehringer Ingelheim Investigational Site
Rennes
China6 sites
1199.32.86001 Boehringer Ingelheim Investigational Site
Beijing
1199.32.86002 Boehringer Ingelheim Investigational Site
Beijing
1199.32.86005 Boehringer Ingelheim Investigational Site
Changsha
1199.32.86004 Boehringer Ingelheim Investigational Site
Chengdu
1199.32.86003 Boehringer Ingelheim Investigational Site
Nanchang
1199.32.86006 Boehringer Ingelheim Investigational Site
Xi'an
Australia5 sites
1199.32.61001 Boehringer Ingelheim Investigational Site
Camperdown, New South Wales
1199.32.61002 Boehringer Ingelheim Investigational Site
Concord, New South Wales
1199.32.61003 Boehringer Ingelheim Investigational Site
Daw Park, South Australia
1199.32.61005 Boehringer Ingelheim Investigational Site
Frankston, Victoria
1199.32.61004 Boehringer Ingelheim Investigational Site
Prahran, Victoria
India5 sites
1199.32.91003 Boehringer Ingelheim Investigational Site
Ahmedabad
1199.32.91002 Boehringer Ingelheim Investigational Site
Coimbatore
1199.32.91006 Boehringer Ingelheim Investigational Site
Jaipur
1199.32.91005 Boehringer Ingelheim Investigational Site
Kolkata
1199.32.91001 Boehringer Ingelheim Investigational Site
Mumbai
Belgium4 sites
1199.32.32004 Boehringer Ingelheim Investigational Site
Brussels
1199.32.32005 Boehringer Ingelheim Investigational Site
Jette
1199.32.32001 Boehringer Ingelheim Investigational Site
Leuven
1199.32.32002 Boehringer Ingelheim Investigational Site
Yvoir
Czechia3 sites
1199.32.42002 Boehringer Ingelheim Investigational Site
Prague
1199.32.42003 Boehringer Ingelheim Investigational Site
Prague
1199.32.42001 Boehringer Ingelheim Investigational Site
Ústí nad Labem
Israel3 sites
1199.32.97004 Boehringer Ingelheim Investigational Site
Haifa
1199.32.97001 Boehringer Ingelheim Investigational Site
Petah Tikva
1199.32.97002 Boehringer Ingelheim Investigational Site
Rehovot
About this study
Official title: A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the death rate.
In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of patients treated with high dose of BIBF 1120 compared to placebo.
Read more
Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data.
Respiratory function is globally accepted for assessment of treatment effects in IPF patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in IPF patients.
- Conditions
- Pulmonary Fibrosis
- Being tested
- placebo, BIBF 1120
- Medical subject headings
- Pulmonary Fibrosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
placeboDrug
placebo matching BIBF1120, BID
BIBF 1120Drug
BIBF1120 BID (twice daily)
| Study group | Role | What they receive |
|---|---|---|
| BIBF 1120 | Experimental | patient receives capsules containing BIBF 1120 twice a day Receives: Drug: BIBF 1120 |
| placebo | Placebo comparator | patient receives capsules identical to those containing active drug Receives: Drug: placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test.
For this endpoint reported means represent the adjusted rate
Measured: 52 weeks
Secondary outcomes (28)
Change From Baseline in Saint-George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks
This is a key secondary endpoint.
SGRQ is a health-related quality of life questionnaire divided into 3 components : symptoms, activity and impact.
The total score (summed weights) can range from 0 to 100 with a lower score denoting a better health status.
Means provided are the adjusted means based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Measured: baseline and 52 weeks
Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
Due to rare events, the median of time to event is not calculable, thus the percentages of patients with (IPF) exacerbation are reported and represented as a key secondary endpoint. An acute exacerbation (reported as an AE by the investigator) was defined as follows:
Otherwise unexplained clinical features including all of the following:
- Unexplained worsening or development of dyspnoea within 30 days
- New diffuse pulmonary infiltrates on chest X-ray, and/or new HRCT parenchymal abnormalities with no pneumothorax or pleural effusion (new ground-glass opacities) since the last visit
- Exclusion of infection as per routine clinical practice and microbiological studies
- Exclusion of alternative causes as per routine clinical practice including left heart failure, pulmonary embolism and identifiable cause of acute lung injury.
Failure is the proportion of patients with at least one acute IPF exacerbation over 52 weeks, based on all investigator-reported AEs .
Measured: 52 weeks
Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Measured: Baseline and 52 weeks
Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Percentage change from baseline in FVC over 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Measured: Baseline and 52 weeks
Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Measured: Baseline and 52 weeks
Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Percentage change from baseline in FVC (% predicted) at 52 weeks. Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Measured: Baseline and 52 weeks
Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 5% threshold (decrease by >5%, increase by >5%, and change within ≤5%).
Measured: Baseline and 52 weeks
Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold
Absolute categorical change of FVC (% predicted) by categories over 52 weeks - 10% threshold (decrease by 10%, increase by >10%, and change within ≤10%)
Measured: Baseline and 52 weeks
FVC Responders Using 10% Threshold at 52 Weeks
FVC responders using 10% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 10% and with an FVC evaluation at 52 weeks.
Measured: 52 weeks
Proportion of FVC Responders Using 5% Threshold at 52 Weeks
Proportion of FVC responders using 5% threshold at 52 weeks, defined as patients with absolute decline in FVC% predicted no greater than 5% and with an FVC evaluation at 52 weeks.
Measured: 52 weeks
Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Proportion of SGRQ responders at 52 weeks
Responders defined as <= -4 points change in change from baseline in SGRQ total score at 52 weeks.
Measured: Baseline and 52 weeks
Change From Baseline in SGRQ Symptom Score at 52 Weeks: Patient Reported Outcomes (PROs)
SGRQ Symptom score is a sub-component of SGRQ total score and is concerned with the effect of respiratory symptoms, their frequency and severity. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better symptom-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Measured: Baseline and 52 weeks
Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
SGRQ Impact score is a sub-component of SGRQ total score and covers a range of aspects concerned with social functioning and psychological disturbances resulting from airway disease. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better impact-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Measured: Baseline and 52 weeks
Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
SGRQ Activity score is a sub-component of SGRQ total score and concerned with activities that cause or are limited by breathlessness. This score calculated as summed weights ranges from 0 to 100 with lower score denoting a better activity-related quality of life.
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Measured: baseline and 52 weeks
Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
SGRQ-I is the IPF specific version of SGRQ comprises of selected items from the SGRQ divided into three components, Symptoms, Activity and Impact. Each component is scored separately. The weights for all items with a positive responses are summed and the weights from missed items are deducted from the maximum possible weight for the total score.
The total score is calculated by dividing the summed weights from positive items in the questionnaire by maximum possible weight for all items in the questionnaire. The total score can range from 0 to 100 with a lower score denoting a better health-related quality of life. Change from baseline is calculated as the difference between total score at week 52 and total score at baseline as measured by the scale.
Measured: Baseline and 52 weeks
Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)
Shortness of Breath Questionnaire measures the shortness of breath. It comprises of 24 items. Each item is scored on a scale between 0-5 where 5 represents maximal breathlessness. The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Measured: baseline and 52 weeks
Change From Baseline in Cough Symptoms Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
The cough domains of the Cough and Sputum Assessment Questionnaire (CASAQ(CD)) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Measured: Baseline and 52 weeks
Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks : Patient Reported Outcomes (PROs)
The cough domains of the Cough and Sputum Assessment Questionnaire (CASA-Q) assess the frequency and severity of cough and sputum and their impact on everyday life. It contains 4 domains cough/sputum symptom and impact with each scale ranging from 0 to 100 with lower scores indicating higher symptoms/impact levels (worst outcome).
Means presented are the adjusted means and are based on all analyzed patients in the model (not only patients with a baseline and measurement at week 52).
Measured: Baseline and 52 weeks
Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Patient's Global Impression of Change (PGI-C) responders are defined as 'Very much better'/ 'Much better'/ 'A little better'/ 'No change'.
Measured: 52 weeks
Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)
The EuroQol 5-dimensional Health State is based on a visual analog scale (EQ-VAS) representing the general patient's health state labelled from 100 (best imaginable health state) to 0 (worst imaginable health state). A higher score indicating a better health state. Change from baseline is calculated as the difference between health state at week 12, 24 and 52 respectively and health state at baseline as measured by the scale.
Measured: baseline, 12 weeks, 24 weeks and 52 weeks
Risk of an Acute IPF Exacerbation Over 52 Weeks
The incidence rate of exacerbations (calculated as the number of patients with at least 1 acute IPF exacerbation divided by the total number of years at risk in years*100)
Measured: 52 weeks
Time to Death Over 52 Weeks
Due to rare events, the median of time to event is not calculable, thus the percentages of patients who did or did not experienced death before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died over 52 weeks (373 days time-period) .
Measured: 52 weeks
Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death due to respiratory causes before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the the proportion of patients who died due to respiratory causes over 52 weeks (373 days time-period).
Measured: 52 weeks
Time to On-treatment Death
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not die before or at last trial medication intake + 28 days were censored at last trial medication intake + 28 days and reported.
Failure is the the proportion of patients who died on-treatment.
Measured: 52 weeks
Time to Death or Lung Transplant Over 52 Weeks
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experience event (death or lung transplant) before or at 372 days after randomisation or last contact date (whichever occurs first) are reported.
Failure is the proportion of patients who died or had lung transplant over 52 weeks (373 days time-period).
Measured: 52 weeks
Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.
Due to rare events, the median of time to event is not calculable, thus the percentages of participants who did or did not experienced death or lung transplant or qualifying for lung transplant over 52 weeks are reported. A patient was considered qualifying for lung transplant by the investigator if he or she fulfilled the following criteria:
FVC <45% predicted or Carbon monoxide diffusion capacity (DL(CO)) <30% pred or Oxygen saturation on pulse oximetry (SpO2) <88% at rest, at sea level (to be adapted for other heights).
These criteria were evaluated by investigators judgement. Failure is the proportion of patients who died or had lung transplant or qualified for lung transplant over 52 weeks (373 days time-period).
Measured: 52 weeks
Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks
Means presented are the adjusted means. Adjusted mean is based on all analyzed patients in the model (not only patients with a change from baseline to week 52)
Measured: Baseline and 52 weeks
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks
Means provided are the adjusted means and are based on all analysed patients in the model (not only patients with a change from baseline to week 52).
Measured: Baseline and 52 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Apr 2011 (estimated)
- Study startApr 2011
- Primary completionOct 2013
- Study completionOct 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (14)Papers the sponsor has linked to this study.
- Other trials for Pulmonary FibrosisStudies of the same condition, open and under way.
- More trials run by Boehringer IngelheimThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Enrolment
- 515 participants (actual)
Sponsor and investigators
- Lead sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Boehringer Ingelheim, Study chair, Boehringer Ingelheim
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01335464
- Sponsor's protocol ID
- 1199.32
- Other IDs
- 2010-024251-87
- Status last verified
- Jun 2016
- First submitted
- 13 Apr 2011
- Last updated
- 25 Jul 2016
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res. 2021 Apr 26;22(1):125. doi: 10.1186/s12931-021-01695-y.
PubMed 33902584Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, Wijsenbeek M, Kreuter M, Stansen W, Quaresma M, Cottin V. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020 Nov 25;21(1):312. doi: 10.1186/s12931-020-01528-4.
PubMed 33239000Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020 Jun 25;55(6):2000085. doi: 10.1183/13993003.00085-2020. Print 2020 Jun.
PubMed 32217654Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020 Jan 8;20(1):3. doi: 10.1186/s12890-019-1030-4.
PubMed 31914963Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS(R) trials. Respir Res. 2019 Apr 11;20(1):71. doi: 10.1186/s12931-019-1037-7.
PubMed 30971229Xu Z, Li H, Wen F, Bai C, Chen P, Fan F, Hu N, Stowasser S, Kang J. Subgroup Analysis for Chinese Patients Included in the INPULSIS(R) Trials on Nintedanib in Idiopathic Pulmonary Fibrosis. Adv Ther. 2019 Mar;36(3):621-631. doi: 10.1007/s12325-019-0887-1. Epub 2019 Feb 7.
PubMed 30729456Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS(R) trials. Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0.
PubMed 30176872Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017 May 19;49(5):1601339. doi: 10.1183/13993003.01339-2016. Print 2017 May.
PubMed 28526798Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC.
PubMed 28388260Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics. 2017 Apr;35(4):479-491. doi: 10.1007/s40273-016-0480-2.
PubMed 28039616Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017 Apr;72(4):340-346. doi: 10.1136/thoraxjnl-2016-208710. Epub 2016 Sep 26.
PubMed 27672117Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, Pelling K, Quaresma M, Lasky JA. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015 Sep 24;16:116. doi: 10.1186/s12931-015-0276-5.
PubMed 26400368Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18.
PubMed 24836310Richeldi L, Cottin V, Flaherty KR, Kolb M, Inoue Y, Raghu G, Taniguchi H, Hansell DM, Nicholson AG, Le Maulf F, Stowasser S, Collard HR. Design of the INPULSIS trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis. Respir Med. 2014 Jul;108(7):1023-30. doi: 10.1016/j.rmed.2014.04.011. Epub 2014 Apr 29.
PubMed 24834811
Study at a glance
From the registry record, last updated by the sponsor on 25 Jul 2016. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 52 Weeks, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of Oral BIBF 1120, 150 mg Twice Daily, on Annual Forced Vital Capacity Decline, in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- ClinicalTrials.gov ID
- NCT01335464
- Acronym / sponsor ID
- 1199.32
- Conditions
- Pulmonary Fibrosis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 515 participants (actual)
- Lead sponsor
- Boehringer IngelheimIndustry (pharma, biotech, devices)
- Study start
- Apr 2011
- Primary completion
- Oct 2013 (actual)
- Study completion
- Oct 2013 (actual)
- First posted
- 14 Apr 2011 (estimated)
- Results
- Posted 13 Feb 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Idiopathic Pulmonary Fibrosis (IPF) is a chronic disease of unknown cause that results in scarring of the lung and there is a high unmet medical need for effective treatment to halt lung function decline, delay or avoid exacerbation (flare-ups), and ultimately to reduce the death rate.
In a large Phase 2 trial (1199.30) (NCT00514683), investigating the effects of 52 weeks of treatment with BIBF 1120 in patients with IPF, a positive effect was seen on lung function of patients treated with high dose of BIBF 1120 compared to placebo.
Hence it is the purpose of this trial to investigate and confirm the efficacy and safety of BIBF 1120 at a high dose in treating patients with IPF, compared with placebo. The trial will be conducted as a prospective, randomised design with the aim to collect safety and efficacy data.
Respiratory function is globally accepted for assessment of treatment effects in IPF patients. The chosen endpoint (Forced Vital Capacity (FVC) decline) is easy to obtain and is part of the usual examinations done in IPF patients.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| BIBF 1120 | Experimental | Drug: BIBF 1120patient receives capsules containing BIBF 1120 twice a day |
| placebo | Placebo comparator | Drug: placebopatient receives capsules identical to those containing active drug |
Who may qualify
- Ages
- 40 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age >= 40 years;
- IPF diagnosed, according to most recent American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), Latin American Thoracic Association (ALAT) IPF guideline for diagnosis and management, within 5 years;
- Combination of High Resolution Computerized Tomography (HRCT) pattern, and if available surgical lung biopsy pattern, as assessed by central reviewers, are consistent with diagnosis of IPF
- Dlco (corrected for Hb): 30%-79% predicted of normal;
- FVC>= 50% predicted of normal
Key exclusion criteria (11 listed)
- Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) > 1.5 x Upper Limit of Normal (ULN)
- Bilirubin > 1.5 x ULN;
- Relevant airways obstruction (i.e. pre-bronchodilator FEV1/FVC < 0.7);
- Patient likely to have lung transplantation during study (being on transplantation list is acceptable for participation);
- Myocardial infarction within 6 months;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| placeboplacebo matching BIBF1120, BID | Drug | placebo |
| BIBF 1120BIBF1120 BID (twice daily) | Drug | BIBF 1120 |
Primary outcome
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks
Time frame: 52 weeks
Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. For this endpoint reported means represent the adjusted rate
28 secondary outcomes
Change From Baseline in Saint-George's Respiratory Questionnaire (SGRQ) Total Score at 52 Weeks
Time frame: baseline and 52 weeks
Time to First Acute Idiopathic Pulmonary Fibrosis (IPF) Exacerbation
Time frame: 52 weeks
Absolute Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Time frame: Baseline and 52 weeks
Relative Change From Baseline in Forced Vital Capacity (FVC) Over 52 Weeks
Time frame: Baseline and 52 weeks
Absolute Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Time frame: Baseline and 52 weeks
Relative Change From Baseline in Forced Vital Capacity (FVC) (% Predicted) Over 52 Weeks
Time frame: Baseline and 52 weeks
Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 5% Threshold
Time frame: Baseline and 52 weeks
Absolute Categorical Change of FVC (% Predicted) by Categories Over 52 Weeks - 10% Threshold
Time frame: Baseline and 52 weeks
FVC Responders Using 10% Threshold at 52 Weeks
Time frame: 52 weeks
Proportion of FVC Responders Using 5% Threshold at 52 Weeks
Time frame: 52 weeks
Proportion of SGRQ Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Time frame: Baseline and 52 weeks
Change From Baseline in SGRQ Symptom Score at 52 Weeks: Patient Reported Outcomes (PROs)
Time frame: Baseline and 52 weeks
Change From Baseline in SGRQ Impact Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Time frame: Baseline and 52 weeks
Change From Baseline in SGRQ Activity Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Time frame: baseline and 52 weeks
Change From Baseline in Idiopathic Pulmonary Fibrosis (IPF) Specific Version of SGRQ (SGRQ-I) Total Score at 52 Weeks (Points): Patient Reported Outcomes (PROs)
Time frame: Baseline and 52 weeks
Change From Baseline in Shortness of Breath Questionnaire (SOBQ) at 52 Weeks: Patient Reported Outcomes (PROs)
Time frame: baseline and 52 weeks
Change From Baseline in Cough Symptoms Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks: Patient Reported Outcomes (PROs)
Time frame: Baseline and 52 weeks
Change From Baseline in Cough Impact Score of the Cough and Sputum Assessment Questionnaire (CASA-Q) Score at 52 Weeks : Patient Reported Outcomes (PROs)
Time frame: Baseline and 52 weeks
Proportion of Patient's Global Impression of Change (PGI-C) Responders at 52 Weeks: Patient Reported Outcomes (PROs)
Time frame: 52 weeks
Change From Baseline in EuroQol 5-Dimensional Quality of Life Questionnaire (EQ-5D) Health State up to 52 Weeks : Patient Reported Outcomes (PROs)
Time frame: baseline, 12 weeks, 24 weeks and 52 weeks
Risk of an Acute IPF Exacerbation Over 52 Weeks
Time frame: 52 weeks
Time to Death Over 52 Weeks
Time frame: 52 weeks
Time to Death Due to Respiratory Cause Over 52 Weeks (Adjudicated)
Time frame: 52 weeks
Time to On-treatment Death
Time frame: 52 weeks
Time to Death or Lung Transplant Over 52 Weeks
Time frame: 52 weeks
Time to Death or Lung Transplant or Qualifying for Lung Transplant Over 52 Weeks.
Time frame: 52 weeks
Change From Baseline in SpO2 (Oxygen Saturation, Expressed in Percent) at Rest up Over 52 Weeks
Time frame: Baseline and 52 weeks
Change From Baseline in Carbon Monoxide Diffusion Capacity (DLCO) at Rest Over 52 Weeks
Time frame: Baseline and 52 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Jul 2016.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 33902584Glaspole I, Bonella F, Bargagli E, Glassberg MK, Caro F, Stansen W, Quaresma M, Orsatti L, Bendstrup E. Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respir Res. 2021 Apr 26;22(1):125. doi: 10.1186/s12931-021-01695-y.
- Derived from this study: PubMed 33239000Jouneau S, Crestani B, Thibault R, Lederlin M, Vernhet L, Valenzuela C, Wijsenbeek M, Kreuter M, Stansen W, Quaresma M, Cottin V. Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respir Res. 2020 Nov 25;21(1):312. doi: 10.1186/s12931-020-01528-4.
- Derived from this study: PubMed 32217654Brown KK, Martinez FJ, Walsh SLF, Thannickal VJ, Prasse A, Schlenker-Herceg R, Goeldner RG, Clerisme-Beaty E, Tetzlaff K, Cottin V, Wells AU. The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J. 2020 Jun 25;55(6):2000085. doi: 10.1183/13993003.00085-2020. Print 2020 Jun.
- Derived from this study: PubMed 31914963Richeldi L, Kolb M, Jouneau S, Wuyts WA, Schinzel B, Stowasser S, Quaresma M, Raghu G. Efficacy and safety of nintedanib in patients with advanced idiopathic pulmonary fibrosis. BMC Pulm Med. 2020 Jan 8;20(1):3. doi: 10.1186/s12890-019-1030-4.
- Derived from this study: PubMed 30971229Kreuter M, Koegler H, Trampisch M, Geier S, Richeldi L. Differing severities of acute exacerbations of idiopathic pulmonary fibrosis (IPF): insights from the INPULSIS(R) trials. Respir Res. 2019 Apr 11;20(1):71. doi: 10.1186/s12931-019-1037-7.
- Derived from this study: PubMed 30729456Xu Z, Li H, Wen F, Bai C, Chen P, Fan F, Hu N, Stowasser S, Kang J. Subgroup Analysis for Chinese Patients Included in the INPULSIS(R) Trials on Nintedanib in Idiopathic Pulmonary Fibrosis. Adv Ther. 2019 Mar;36(3):621-631. doi: 10.1007/s12325-019-0887-1. Epub 2019 Feb 7.
- Derived from this study: PubMed 30176872Costabel U, Behr J, Crestani B, Stansen W, Schlenker-Herceg R, Stowasser S, Raghu G. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS(R) trials. Respir Res. 2018 Sep 3;19(1):167. doi: 10.1186/s12931-018-0866-0.
- Derived from this study: PubMed 28526798Collard HR, Richeldi L, Kim DS, Taniguchi H, Tschoepe I, Luisetti M, Roman J, Tino G, Schlenker-Herceg R, Hallmann C, du Bois RM. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017 May 19;49(5):1601339. doi: 10.1183/13993003.01339-2016. Print 2017 May.
- Derived from this study: PubMed 28388260Paterniti MO, Bi Y, Rekic D, Wang Y, Karimi-Shah BA, Chowdhury BA. Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 Sep;14(9):1395-1402. doi: 10.1513/AnnalsATS.201606-458OC.
- Derived from this study: PubMed 28039616Rinciog C, Watkins M, Chang S, Maher TM, LeReun C, Esser D, Diamantopoulos A. A Cost-Effectiveness Analysis of Nintedanib in Idiopathic Pulmonary Fibrosis in the UK. Pharmacoeconomics. 2017 Apr;35(4):479-491. doi: 10.1007/s40273-016-0480-2.
- Derived from this study: PubMed 27672117Kolb M, Richeldi L, Behr J, Maher TM, Tang W, Stowasser S, Hallmann C, du Bois RM. Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax. 2017 Apr;72(4):340-346. doi: 10.1136/thoraxjnl-2016-208710. Epub 2016 Sep 26.
- Derived from this study: PubMed 26400368Corte T, Bonella F, Crestani B, Demedts MG, Richeldi L, Coeck C, Pelling K, Quaresma M, Lasky JA. Safety, tolerability and appropriate use of nintedanib in idiopathic pulmonary fibrosis. Respir Res. 2015 Sep 24;16:116. doi: 10.1186/s12931-015-0276-5.
Related trials for Pulmonary Fibrosis
Active, not recruitingObservational study
CFTR Modulator Effects on Bone and Muscle in Adults With Cystic Fibrosis
Cystic Fibrosis, Bone Loss
RecruitingPhase 2
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
RecruitingObservational study
Natural History of Bronchiectasis
Bronchiectasis, Cystic Fibrosis
Active, not recruitingPhase 2
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
RecruitingObservational study
Role of Genetic Factors in the Development of Lung Disease
Cystic Fibrosis, Pulmonary Fibrosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Boehringer Ingelheim study chair
Boehringer Ingelheim
98 sites in 13 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing BIBF 1120 in people with Pulmonary Fibrosis, run by Boehringer Ingelheim at 98 sites in 13 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Jul 2016. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 98 sites in United States, Italy, Japan, Germany, United Kingdom and 8 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 13 Feb 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Annual Rate of Decline in Forced Vital Capacity (FVC) Over 52 Weeks (time frame: 52 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01335464, which also lists 14 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jul 2016.